Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00515944

Enrollment

Registered

2007-08-14

Start date

2007-08-31

Completion date

2008-06-30

Last updated

2009-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

No condition, healthy volunteers

Brief summary

Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening. Botulinum toxin type A is used for certain neurological and aesthetic treatments. This study will investigate the migration potential of Xeomin®.

Detailed description

Conducted in Europe

Interventions

DRUGBotulinum neurotoxin type A, free of complexing proteins

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Masking

DOUBLE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy females, 18 to 65 years

Design outcomes

Primary

Measure	Time frame
Measurement of area	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026